Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Takeda Development Center Americas, Inc., Lexington, MA, USA

6 abstracts

14 posters

Poster
Molecular Analysis of Circulating Tumor DNA in Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC Treated With Mobocertinib
Poster
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC
Poster
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion (ex20ins) mutations identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)
Poster
Brigatinib in Japanese Patients With ALK+ NSCLC: Final Results From the Phase 2 J-ALTA Trial
Poster
Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions (ex20ins)
Poster
Association of Depth of Target Lesion Response to Brigatinib With Outcomes in Patients With ALK Inhibitor-Naive ALK+ NSCLC in ALTA-1L
Poster
TAK-676 in combination with pembrolizumab after radiation therapy in patients with advanced non–small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design
Poster
Phase 1a/1b study of the novel STING agonist immune stimulating antibody conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors
Poster
Mobocertinib (TAK-788) in EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: treatment beyond progressive disease in platinum-pretreated patients with and without intracranial progressive disease
Poster
Brigatinib in Japanese Patients With ALK+ NSCLC: Final Results From the Phase 2 J-ALTA Trial
Poster
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion (ex20ins) mutations identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)
Poster
Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions (ex20ins)
Poster
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC
Poster
Molecular Analysis of Circulating Tumor DNA in Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC Treated With Mobocertinib
Abstract
Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
Org: Versiti Blood Research Institute, Division of Hematology and Oncology, Medical College of Wisconsin, Imperial College London, Royal North Shore Hospital, Singapore General Hospital, Duke-NUS Medical School,
Abstract
Brigatinib monotherapy in children with R/R ALK+ ALCL, IMT, or other solid tumors: Results from the BrigaPED (ITCC-098) phase 1 study.
Org: Princess Máxima Center for Pediatric Oncology, Erasmus MC-Sophia Children’s Hospital, University Medical Center Hamburg-Eppendorf, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Children University Hospital,
Abstract
Feasibility and utilization of electronic patient-reported outcome measures for lung cancer in routine clinical care.
Org: Takeda Development Center Americas, Inc., Lexington, MA, USA, Takeda Pharmaceutical Company Limited, Osaka, Japan, Carevive Systems, Inc., Piedmont Research Strategies,
Abstract
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
Org: Stanford University Medical Center, Stanford, CA, Takeda Development Center Americas, Inc., Lexington, MA, USA, Takeda Pharmaceuticals USA, Inc., Massachusetts General Hospital,
Abstract
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic College of Medicine, Takeda Development Center Americas, Inc., Lexington, MA, USA,
Abstract
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
Org: University of Colorado Cancer Center, Sendai Kousei Hospital, Fujita Health University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System,